Articles By Anuja Singh
Lantern Pharma Secures FDA Orphan Drug Designation for LP-284 in Soft Tissue Sarcomas, Expanding…
Dallas, U.S. | January 20, 2026 Lantern Pharma has strengthened its precision oncology pipeline after the U.S. Food…
ByCan Amgen’s 2025 Approvals and Launches Strengthen Its Oncology, Cardiovascular, and Bone Health Leadership…
Global | January 2026 — Amgen Inc. achieved key milestones in 2025, marked by multiple regulatory approvals, label…
Can GSK’s 2025 Approvals and Launches Strengthen Its Vaccines, Respiratory, and Immunology Leadership Into…
Global | January 2026 — GlaxoSmithKline PLC (GSK) achieved key milestones in 2025, with multiple regulatory approvals, product…
Can AstraZeneca’s 2025 Launches and Approvals Strengthen Its Oncology, Cardiovascular, and Respiratory Leadership Into…
Global | January 2026 — AstraZeneca PLC achieved significant milestones in 2025, marked by multiple regulatory approvals, label…
Can Novo Nordisk’s 2025 Diabetes, Obesity, and Rare Disease Launches Drive Sustainable Growth Into…
Global | January 2026 — Novo Nordisk A/S continued to reinforce its leadership in diabetes, obesity, and rare…
Can Roche’s 2025 Launches and Approvals Reinforce Its Leadership in Oncology, Diagnostics, and Neuroscience…
Global | January 2026 — Roche Holding AG achieved a strong year in 2025, marked by multiple regulatory…
Lantern Pharma Secures FDA Orphan Drug Designation for LP-284 in Soft Tissue Sarcomas, Expanding…
Dallas, U.S. | January 20, 2026 Lantern Pharma has strengthened its precision oncology pipeline after the U.S. Food…
Can Amgen’s 2025 Approvals and Launches Strengthen Its Oncology, Cardiovascular, and Bone Health Leadership…
Global | January 2026 — Amgen Inc. achieved key milestones in 2025, marked by multiple regulatory approvals, label…
Can GSK’s 2025 Approvals and Launches Strengthen Its Vaccines, Respiratory, and Immunology Leadership Into…
Global | January 2026 — GlaxoSmithKline PLC (GSK) achieved key milestones in 2025, with multiple regulatory approvals, product…
Can AstraZeneca’s 2025 Launches and Approvals Strengthen Its Oncology, Cardiovascular, and Respiratory Leadership Into…
Global | January 2026 — AstraZeneca PLC achieved significant milestones in 2025, marked by multiple regulatory approvals, label…
Can Novo Nordisk’s 2025 Diabetes, Obesity, and Rare Disease Launches Drive Sustainable Growth Into…
Global | January 2026 — Novo Nordisk A/S continued to reinforce its leadership in diabetes, obesity, and rare…
Can Roche’s 2025 Launches and Approvals Reinforce Its Leadership in Oncology, Diagnostics, and Neuroscience…
Global | January 2026 — Roche Holding AG achieved a strong year in 2025, marked by multiple regulatory…